Afrezza
Arzerra approved by US FDA for leukaemia
January 20, 2016Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application
The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …
Sanofi abandons MannKind’s failed inhalable insulin
January 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing Afrezza, Mannkind, Sanofi, insulin
Sanofi is to exit a licensing and co-marketing deal with MannKind for the inhalable insulin Afrezza, after disappointing sales figures …
Sanofi sees FDA approval for diabetes drug
February 26, 2015Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4
US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …
Sanofi signs $925 million inhaled insulin deal
August 13, 2014Sales and Marketing Afrezza, French, Sanofi, diabetes, fad, insulin
Sanofi could pay out as much as $925 million for global rights to the world’s only approved inhaled insulin just …
FDA ‘yes’ to inhaled insulin
June 30, 2014Manufacturing and Production, Sales and Marketing Afrezza, FDA, Mannkind, diabetes, insulin human
The FDA has approved the first ‘ultra-rapid-acting’ mealtime insulin therapy available in the US, to improve glycemic control in both …
Inhaled insulin one step closer to approval
April 3, 2014Sales and Marketing Afrezza, FDA, Mannkind, diabetes, type 1, type 2
After a rocky few years MannKind’s inhaled insulin Afrezza finally looks to be on the path to approval in the …
